SCHEDULE: Atlas Venture Funds Adjust Kymera Therapeutics Stake

Atlas Venture Fund X, L.P. and related entities have reported a change in their beneficial ownership of Kymera Therapeutics, Inc. common stock, now holding 3.4% collectively.

Summary

• This filing is an amendment to a Schedule 13G, reporting changes in beneficial ownership of Kymera Therapeutics, Inc. common stock by various Atlas Venture entities.
• The reporting persons include Atlas Venture Fund X, L.P., Atlas Venture Associates X, L.P., Atlas Venture Associates X, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., and Atlas Venture Associates Opportunity I, LLC.
• Collectively, these entities beneficially own 2,847,541 shares of common stock, representing 3.4% of the issuer's outstanding shares.
• This percentage is calculated based on 83,150,618 outstanding shares as of July 31, 2026, as reported in Kymera Therapeutics' 10-Q filing on August 5, 2026.
• The filing details shared voting and dispositive power among the reporting persons for the shares they hold.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a change in beneficial ownership percentage, indicating a shift in investment strategy rather than company performance.

Positives

• The reporting entities collectively hold a significant, though not controlling, stake in Kymera Therapeutics.
• The filing provides transparency regarding the ownership structure and investment positions of Atlas Venture entities.

Negatives

• The filing indicates a potential shift in investment strategy by Atlas Venture, which could be interpreted as a reduced conviction or a rebalancing of their portfolio.
• The aggregate ownership of 3.4% is below the threshold that typically triggers significant influence or control.

Risks

• Changes in beneficial ownership by significant investors can sometimes precede further strategic actions, such as additional sales or shifts in voting power, which could impact share price.
• While not explicitly stated as a risk, a decrease in a major investor's stake could signal concerns about future company performance or valuation.

Future Outlook

No specific forward-looking statements or guidance are provided in this Schedule 13G filing, as it pertains to ownership changes.

Industry Context

StockSavvy.ai notes that venture capital firms frequently adjust their holdings in publicly traded portfolio companies. This filing reflects a typical portfolio management activity within the biotechnology and pharmaceutical sectors, where investment theses can evolve based on clinical trial progress, market conditions, and strategic opportunities.

Comparison to Industry Standards

• Venture capital firms typically hold significant stakes in their portfolio companies, often ranging from 5% to 20% or more, especially in earlier stages. A 3.4% stake is common for later-stage or post-IPO investments where the firm may be reducing its position or rebalancing.
• Competitors in the venture capital space, such as other biotech-focused funds, also engage in similar portfolio adjustments. For instance, firms like ARCH Venture Partners or Flagship Pioneering are known for their active management of their public and private biotech investments.

Stakeholder Impact

• Shareholders: May interpret the change in beneficial ownership as a signal of Atlas Venture's evolving view on the company's prospects, potentially influencing trading decisions.
• Company Management: May need to engage with Atlas Venture to understand their strategic rationale and ensure alignment on future company direction.

Next Steps

• Continued monitoring of Atlas Venture's ownership levels in Kymera Therapeutics.
• Observation of any further disclosures or strategic announcements from Kymera Therapeutics that might be influenced by investor sentiment.

Key Dates

Keywords

Kymera Therapeutics, Atlas Venture, Schedule 13G, Beneficial Ownership, Common Stock, Investment Funds, Venture Capital